- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Coverage Decisions for Personalized Medicine
Although he does not make coverage decisions, David C. Collymore, MD, MBA, believes that in the field of oncology, the science has reached a point where it has recognized certain treatments are better suited for some individuals with a specific genetic predisposition. “Cancer research is almost the standard of care for that to be the mindset for oncologists,” Dr. Collymore explained.
He believes that the progress in the field of oncology should trickle over to other disease areas. “We do see some of that in HIV treatment, like testing for resistance to certain medications. So there’s a tailored approach in other aspects of healthcare too. The next step would be for this to trickle down to more prevalent (chronic) conditions such as diabetes and hypertension that have affected our nation,” said Dr. Collymore.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Technology Takes Center Stage at the 2025 AAD Annual Meeting
March 14th 2025The role of artificial intelligence, DataDerm, and telehealth in advancing dermatology care was discussed throughout the meeting, with experts highlighting their potential regarding patient access and health equity.
Read More
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
